Top neuro stories of 2021: Aduhelm news, neurologic COVID-19 symptoms

Healio Neurology’s most-viewed stories from 2021 highlight developments surrounding Aduhelm, the benefits of flavonoid on cognitive function and neurologic symptoms in COVID-19.

FDA approves Aduhelm, first new Alzheimer's disease treatment since 2003

The FDA today granted accelerated approval for Aduhelm, the first new treatment to be approved for Alzheimer’s disease since 2003. Read more.

FDA calls for a federal investigation into Aduhelm approval

The FDA called for a federal investigation into the approval of Aduhelm for the treatment of patients with Alzheimer’s disease, as reported by STAT. Read more.

High flavonoid intake benefits cognitive function in study of American men, women

Increased flavonoid consumption reduced the risk of subjective cognitive decline among men and women in the U.S., according to findings published in Neurology. Read more.

Cognitive impairment somewhat common after COVID-19 infection

Cognitive impairment occurred relatively often within several months of patients having had COVID-19, according to results of a cross-sectional study published in JAMA Network Open. Read more.

Most common neurologic symptoms in COVID-19 ‘long-haulers’ include brain fog, headache

Non-hospitalized ‘long hauler’ patients with COVID-19 experienced “prominent and persistent” neurological symptoms, including brain fog and fatigue, according to results published in Annals of Clinical and Translational Neurology. Read more.